Alafair Biosciences says it made the 2026 Inc. 5000 list for the fourth straight year
Alafair Biosciences said on Aug. 11 that it was named to the 2026 Inc. 5000 list after launching VersaCoat Flowable Hydrogel.
Alafair Biosciences said on Aug. 11 that it was named to the 2026 Inc. 5000 list for the fourth consecutive year.
The Austin-based medical device company said the recognition follows the recent launch of VersaCoat Flowable Hydrogel, a syringe-deliverable product built on its VersaCore Hydrogel Technology. The company said the product expands its portfolio in soft-tissue protection for orthopedic surgery.
Background and context
In its release, Alafair described VersaCoat Flowable Hydrogel as a naturally derived, bioresorbable hydrogel based on hyaluronic acid and alginate. The company said it is intended to create a conformable, tissue-adherent gliding interface for procedures involving tendons, peripheral nerves, ligaments, skeletal muscle and related anatomy.
Inc. describes the Inc. 5000 as its annual ranking of the fastest-growing private companies in the U.S. The company said the 2026 list includes 5,000 companies, with a median three-year revenue growth rate of 130% and more than 627,208 jobs added collectively over the past three years.
Alafair also pointed to VersaCoat as a new addition to a product line that already includes VersaWrap Hydrogel Sheet.
Alafair said VersaWrap has been used in more than 40,000 implants across multiple specialties and healthcare systems.
What the company said
President and CEO John Joyoprayitno said the fourth straight Inc. 5000 placement validates the team’s work. He said the company expects continued growth from expansion of its sales channel and the recent launch of VersaCoat Flowable Hydrogel.
What happens next
Alafair did not announce any new financial targets or public timetable in the release.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
View the Web StoryA visual, tap-through version of this reportThis is the AMP version of the article. Read the full article on Atlas Watchline.